U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H40O5
Molecular Weight 432.5928
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of LATANOPROST

SMILES

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC2=CC=CC=C2

InChI

InChIKey=GGXICVAJURFBLW-CEYXHVGTSA-N
InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1

HIDE SMILES / InChI
Molecular Formula C26H40O5
Molecular Weight 432.5928
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 1
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/29194198 | https://clinicaltrials.gov/ct2/show/NCT01895972 | https://www.ncbi.nlm.nih.gov/pubmed/28783422 | https://clinicaltrials.gov/ct2/show/NCT01749904

Latanoprost (free acid) is a metabolite of latanoprost which has been approved for use as an ocular hypotensive drug. Latanoprost is an isopropyl ester prodrug which is converted to the Latanoprost-acid by endogenous esterase enzymes. The free acid is pharmacologically active and is 200 times more potent than latanoprost as an agonist of the human recombinant Prostaglandin F receptor. However, the free Latanoprost-acid is more irritating and less effective than Latanoprost when applied directly to the eyes of human glaucoma patients.

Originator

Approval Year

1995
186
Targets

Targets

Primary TargetPharmacologyConditionPotency
Prostaglandin F2-alpha receptor
12
Target ID: P43088
Gene ID: 5737.0
Gene Symbol: PTGFR
Target Organism: Homo sapiens (Human)
Agonist
2662
 3.6 nM [EC50]
Agonist
2662
Agonist
2662
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
VYZULTA

Approved Use

VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Launch Date

1.48668482E12
Primary
Approved
8360
VYZULTA

Approved Use

VYZULTA is a prostaglandin analog indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension

Launch Date

1.48668482E12
Primary
Approved
8360
VYZULTA

Approved Use

YZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Launch Date

1.50949436E12
Primary
Approved
8360
VYZULTA

Approved Use

YZULTA™ (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Launch Date

1.50949436E12
Palliative
Approved
8360
XALATAN

Approved Use

XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Launch Date

8.3393282E11
Primary
Approved
8360
XALATAN

Approved Use

XALATAN Sterile Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Launch Date

8.3393282E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
53 pg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12204697/
1.5 μg single, ocular
dose: 1.5 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
LATANOPROST ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7.15 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12204697/
3 μg/kg bw single, intravenous
dose: 3 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LATANOPROST ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
34 pg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12204697/
1.5 μg single, ocular
dose: 1.5 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
LATANOPROST ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
16.6 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12204697/
3 μg/kg bw single, intravenous
dose: 3 μg/kg bw
route of administration: Intravenous
experiment type: SINGLE
co-administered:
LATANOPROST ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
17 min
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/12204697/
1.5 μg single, ocular
dose: 1.5 μg
route of administration: Ocular
experiment type: SINGLE
co-administered:
LATANOPROST ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.005 % 1 times / day multiple, topical
Recommended
Dose: 0.005 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.005 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
unhealthy, mean age 63.1 years
n = 289
Health Status: unhealthy
Condition: open-angle glaucoma | ocular hypertension
Age Group: mean age 63.1 years
Sex: M+F
Population Size: 289
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
Disc. AE: Iritis, Meibomianitis...
AEs leading to
discontinuation/dose reduction:
Iritis (grade 2, 0.3%)
Meibomianitis (grade 1, 0.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
11 ug/kg multiple, topical
MTD
Dose: 11 ug/kg
Route: topical
Route: multiple
Dose: 11 ug/kg
Sources:
https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf
unhealthy
Health Status: unhealthy
Sources:
https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf
Sources:
https://www.ema.europa.eu/en/documents/referral/xalatan-article-29-paediatrics-chmp-assessment-report_en.pdf
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Other AEs: Abdominal pain, Dizziness...
Other AEs:
Abdominal pain
Dizziness
Fatigue
Hot flushes
Nausea
Sweating
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Meibomianitis grade 1, 0.3%
Disc. AE
0.005 % 1 times / day multiple, topical
Recommended
Dose: 0.005 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.005 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
unhealthy, mean age 63.1 years
n = 289
Health Status: unhealthy
Condition: open-angle glaucoma | ocular hypertension
Age Group: mean age 63.1 years
Sex: M+F
Population Size: 289
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
Iritis grade 2, 0.3%
Disc. AE
0.005 % 1 times / day multiple, topical
Recommended
Dose: 0.005 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.005 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
unhealthy, mean age 63.1 years
n = 289
Health Status: unhealthy
Condition: open-angle glaucoma | ocular hypertension
Age Group: mean age 63.1 years
Sex: M+F
Population Size: 289
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/206185Orig1s000StatR.pdf
Abdominal pain
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Dizziness
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Fatigue
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Hot flushes
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Nausea
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Sweating
10 ug/kg single, intravenous (max)
Overdose
Dose: 10 ug/kg
Route: intravenous
Route: single
Dose: 10 ug/kg
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
healthy
Health Status: healthy
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020597s052lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP450
25
CYP
266

OATP2B1
103

MRP1
106

MRP2
201

MRP5
40

P-gp
1527

BCRP
555
CYP450
32
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP450
41
 unlikely
CYP450
41
 unlikely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
266
 no
P-gp
1527
 no
BCRP
555
 unlikely
OATP2B1
103
 weak
MRP1
106
 yes
MRP2
201
 yes
MRP5
40
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA00BXFY
https://www.aablocks.com/goods/Goods/detail?id=AA00BXFY
AK Scientific, Inc. (AKSCI)
Z6154
http://www.aksci.com/item_detail.php?cat=Z6154
Aaron Chemicals
AR00BY7Q
http://www.aaronchem.com/41639-83-2
Achemtek
0104-022891
http://www.achemtek.com/41639-83-2
Alfa Chemistry
AP41639832-B
https://reagents.alfa-chemistry.com/product/latanoprost-acid-cas-41639-83-2-11265.html
Alfa Chemistry
AP41639832-A
https://reagents.alfa-chemistry.com/product/latanoprost-related-compound-e-cas-41639-83-2-11264.html
Ambinter
Amb15690628
http://www.ambinter.com/reference/15690628
Aurora Fine Chemicals LLC
A17.898.261
http://online.aurorafinechemicals.com/info?ID=A17.898.261
AvaChem Scientific
2038
http://www.avachem.com/productSearch.asp?2038
Chem Scene
CS-0068357
http://www.chemscene.com/41639-83-2.html
ChemMol
99087782
http://www.chemmol.com/chemmol/99087782.html
Chemspace
CSSB00020648370
https://chem-space.com/CSSB00020648370
Glentham Life Sciences
GL6689
http://www.glentham.com/products/product/GL6689/
Lab Network
LN01304996
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01304996
MedChem Express
HY-113756A
https://www.medchemexpress.com/latanoprost-acid.html
OChem
18671
http://www.ocheminc.com/index.php?act=psearch&pid=639L832
Sigma-Aldrich
L1292_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/l1292?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1357533_USP
https://www.sigmaaldrich.com/catalog/product/usp/1357533?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S532544
http://www.smolecule.com/products/s532544
THE BioTek
bt-272608
https://www.thebiotek.com/product/inhibitors/bt-272608
eNovation Chemicals
D592348
https://www.enovationchem.com/ProductDetails.asp?ProductID=D592348
eNovation Chemicals
D758325
https://www.enovationchem.com/ProductDetails.asp?ProductID=D758325
iChemical
EBD26372
http://www.ichemical.com/products/41639-83-2.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure.
1993 May
A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study.
1996 Aug
Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
1996 Jan
Mechanism of prostaglandin E2-, F2alpha- and latanoprost acid-induced relaxation of submental veins.
1997 Dec 11
The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma.
1997 Feb
Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure.
1997 Sep
Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability.
1998 Apr
Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma.
1998 May
A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy.
2000 Jul-Sep
[Increased iris pigmentation after use of latanoprost in Japanese brown eyes].
2001 May
Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
2002 Jan
Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma.
2004 Sep
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
2013 Nov
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.
2015 May 18
Patents

Patents

06927300
5
07157590
5
20050272743
5
20080058392
5
20090030076
5
20100130507
5
20110136904
5
7273946
5
7449469
5
7629345
5
7910767
5
8058467
5
JP2002538105A
8
JP2006520758A
17
JP2008037782A
5
JP2009137971A
5
JP4773721B2
17

Sample Use Guides

In Vivo Use Guide
One drop in the affected eye(s) once daily in the evening.
Route of Administration: Other
In Vitro Use Guide
Latanoprost above concentrations of 3.125 mg/l can induce dose- and time-dependent morphological abnormality, growth retardation, viability decline, and plasma membrane permeability elevation of human corneal stromal (HCS) cells. Moreover, latanoprost can arrest the cell cycle of these cells at S phase and induce PS externalization, DNA fragmentation, and apoptotic body formation of the cells. Furthermore, latanoprost can induce activation of caspase-3, -8 and -9; disruption of MTP; downregulation of anti-apoptotic Bcl-2; upregulation of pro-apoptotic Bax; and cytoplasmic cytochrome c release
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:08:45 UTC 2023
Edited
by admin
on Wed Jul 05 23:08:45 UTC 2023
Record UNII
6Z5B6HVF6O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LATANOPROST
INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate
Systematic Name English
PHXA41
Code English
LATANOPROST [MART.]
Common Name English
5-HEPTENOIC ACID, 7-(3,5-DIHYDROXY-2-(3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)-1-METHYLETHYL ESTER, (1R-(1.ALPHA.(Z),2.BETA.(R*),3.ALPHA.,5.ALPHA.))-
Common Name English
XA-41
Code English
T2345
Code English
T-2345
Code English
LATANOPROST [ORANGE BOOK]
Common Name English
latanoprost [INN]
Common Name English
XELPROS
Brand Name English
Latanoprost [WHO-DD]
Common Name English
LATANOPROST COMPONENT OF ROCKLATAN
Common Name English
XALATAN
Brand Name English
LATANOPROST [MI]
Common Name English
ROCKLATAN COMPONENT LATANOPROST
Common Name English
LATANOPROST (ISOPROPYL ESTER)
Common Name English
LATANOPROST [USAN]
Common Name English
LATANOPROST [JAN]
Common Name English
XA41
Code English
LATANOPROST [USP-RS]
Common Name English
IYUZEH
Brand Name English
LATANOPROST [EP MONOGRAPH]
Common Name English
LATANOPROST [USP MONOGRAPH]
Common Name English
LATANOPROST [VANDF]
Common Name English
PHXA-41
Code English
XALACOM COMPONENT LATANOPROST
Brand Name English
Classification Tree Code System Code
WHO-VATC QS01EE01
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
NDF-RT N0000007706
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
NCI_THESAURUS C29705
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
WHO-ATC S01EE01
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
NDF-RT N0000007706
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
NDF-RT N0000175454
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
NCI_THESAURUS C78568
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
NDF-RT N0000007706
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
Code System Code Type Description
DAILYMED
6Z5B6HVF6O
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
EPA CompTox
DTXSID1041057
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
SMS_ID
100000092301
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
USAN
II-6
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
LACTMED
Latanoprost
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
ChEMBL
CHEMBL1051
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
CHEBI
6384
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
INN
6980
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
MESH
C072042
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
NCI_THESAURUS
C29151
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
WIKIPEDIA
LATANOPROST
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
CAS
130209-82-4
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
DRUG CENTRAL
1551
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
EVMPD
SUB08409MIG
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
FDA UNII
6Z5B6HVF6O
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
RS_ITEM_NUM
1357475
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
DRUG BANK
DB00654
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
RXCUI
43611
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY RxNorm
IUPHAR
1961
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
PUBCHEM
5311221
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY
MERCK INDEX
M6701
Created by admin on Wed Jul 05 23:08:45 UTC 2023 , Edited by admin on Wed Jul 05 23:08:45 UTC 2023
PRIMARY Merck Index
Related Record Type Details
Structure of LATANOPROST ACID
METABOLITE ACTIVE -> PRODRUG
Structure of LATANOPROSTENE BUNOD
PARENT -> METABOLITE
Structure of 1,2,3,4-TETRANOR LATANOPROST ACID, LACTONE-
METABOLITE -> PARENT
There is an equilibrium between the acid and the lactone
MAJOR
FECAL; URINE
Structure of 1,2-DINOR LATANOPROST ACID
METABOLITE -> PARENT
MAJOR
FECAL; URINE
Structure of 1,2,3,4-TETRANOR LATANOPROST ACID
METABOLITE -> PARENT
MAJOR
FECAL; URINE
Related Record Type Details
Structure of PROPAN-2-YL (5Z)-7-((1R,2R,3R,5S)-3-(FORMYLOXY)-5-HYDROXY-2-((3R)-3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)HEPT-5-ENOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of PROPAN-2-YL (5Z)-7-((1R,2R,3R,5S)-5-(FORMYLOXY)-3-HYDROXY-2-((3R)-3-HYDROXY-5-PHENYLPENTYL)CYCLOPENTYL)HEPT-5-ENOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of PROPAN-2-YL (5Z)-7-((1R,2R,3R,5S)-2-((3R)-3-(FORMYLOXY)-5-PHENYLPENTYL)-3,5-DIHYDROXYCYCLOPENTYL)HEPT-5-ENOATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Isopropyl 5-(Diphenylphosphoryl)pentanoate
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LATANOPROST TRIS(TRIETHYLSILYL) ETHER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LATANOPROST ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LATANOPROST, (15S)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LATANOPROST, (5E)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LATANOPROST METHYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of LATANOPROST ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966